Changes of hsCRP levels induced by different application ways of estrogene replacement therapy;Vliv různých aplikačních forem estrogenní substituční terapie na hladiny C-reaktivního proteinu

Casopis Lekaru Ceskych

Volumn 145, Issue 7, 2006, Pages 571-574

  Fait, Tomáš ^a,b   Vrablik M ^a   Kostirova, M ^a   Trnkova B ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NONE   (Czech Republic)

Author keywords

Cardiovascular diseases; High sensitive C reactive protein; Hormone replacement therapy

Indexed keywords

C REACTIVE PROTEIN; ESTROGEN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

EID: 33747597584     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Fait, T., Málková, J., Živný, J.: Vliv hormonální substituční terapie na kardiovaskulární systém. Čes. Gynek., 2002, 67, s. 285-293.
2. Fait, T., Vokrouhlická, J., Vrablík, M. et al.: Současné postavení hormonální substituční terapie. Čas. Lék. čes., 2004, 143, s. 447-452.
3. Fait, T., Vrablík, M.: Změny lipidového spektra při užívání hormonální substituční terapie. Čas. Lék. čes., 2004, 143, s. 101-105.
4. Libby, P., Ridker, P. M., Maseri, A.: Inflammation and atherosclerosis. Circulation, 2002, 105, s. 1135-1143.
5. Yeh, E. T. H., Anderson, V., Pasceri, V. et al.: C-reactive protein linking inflammation to cardiovascular complications. Circulation, 2001, 103, s. 974-975.
6. Maruna, P.: Proteiny akutní fáze. Maxdorf, Praha, 2004, s. 282.
7. Ridker, P. M.: HSCRP Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation, 2001, 103, s. 1813-1818.
8. Pasceri, V., Willerson, J. T., Yeh, E. T.: Direct proinflammatory effect of CRP on human endothelian cells. Circulation, 2000, 102, s. 2165-2168.
9. Sellmayer, A., Limmert, T., Hoffmann, U.: High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or usefull screening? Int. Angiol., 2003, 22, s. 15-23.
10. Perason, T. A., Mensah, G. A., Alexander, R. W. et al.: AHA/CDC scientific statement. Markers of inflammation and cardiovascular disease. Circulation, 2003, 107, s. 499-511.
11. Ridker, P. M., Hennekens, C. H., Buring, J. E. et. al.: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disese in women. NEJM, 2000, 342, s. 836-843.
12. Čepický, P., Burdová, M., Cibula, D. et al.: Doporučení k hormonální terapii a substituci perimenopauzy a postmenopauzy. Čes. Gynek., 2003, 68, s. 125-127.
13. Jeníček, J.: Hormonální substituč ní terapie a klimakterium. Praha, Grada., 2001, 101 s.
14. Salpeter, S. R., Walsh, J. M. E., Greyber, E. et al.: Mortality sssociated with HRT in younger and older women. J. Gen. Intern. Med., 2004, 19, s. 791-804.
15. Ridker, P. M., Hennekens, C. H, Rifai, N. et al.: HRT and incresed plasma concentration of C-reactive protein. Circulation, 1999, 100, s. 712-722.
16. Hulley, S., Grady, D., Bush, T. et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA, 1998, 280, s. 605-613.
17. Cushman, M., Legault, C., Barret-Connor, E. et al.: Effect of postmenopausal hormones on inflammation-sensitive proteins the postmenopausal estrogen/progestin intervention (PEPI) study. Circulation, 1999, 100, s. 717-722.
18. Modena, M, G., Sismondi, P., Mueck, A, O. et al.: New evidence regarding HRT is urgently required. Transdermal postmenopausal hormone therapy differs from oral hormone therapy in risk and benefits. Maturitas. 2005, 52, s. 1-10.
19. Koh, K. K., Ahn, J. Y., Kim, D. S. et al.: Effect of HRT on tissue factor activity, C-reactive protein, and the TFPI. Am. J. Cardiology, 2003, 91, s. 371-373.
20. Lowe, G. D., Upton, M. N., Rumley, A. et al.: Different effects of oral and transdermal HRT on factor IX, APC resistance, t-PA, PAI and C=reactive protein - a cross-sectional population survey. Tromb. Haemost., 2000, 86, s. 550-556.
21. Zegura, B., Keber, I., Sebestjen, M. et al.: Different effects of oral and transdermal estradiol replacement on inflamatory markers. Climacteric, 2000, 5 (Suppl. 1), s. 99.
22. Bukowska, H., Stanosz, S., Zochowska, E. et al.: Does the type of HRT affect lipoprotein (a), homocystein, and C-reactive protein levels in postmenopausal women? Metabolism, 2005, 54, s. 72-78.
23. Post, M. S., van der Mooren , M. J., Stehouwer, C. D. A. et al.: Effects of transdermal and oral oestrogen replacement therapy on C-reactive protein levels in postmenopausal women: a randomised, placebo-controlled trial. Thromb. Haemost., 2002, 88, s. 605-610.
24. Koh, K. K, Shin, M. S, Sakuma, I. et al.: Effects of conventional or lower doses of HRT in postmenopausal women, Arteriscler. Thromb. Vase. Biol., 2004, 24, s. 1516-1521.
25. Prelevic, G. M., Kwong, P., Byrne, D. J. et al.: A cross- sectional study of the effets of HRT on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil. Steril., 2002, 77, s. 945-951.
26. Kvasnička, J., Donát, J., Šormová, I.: Serum C-reactive protein, SE-selectin, SICAM-1 and alpha-2-makroglubulin concentrations in women with percutaneous 17-beta-estradiol substitution. Climacteric, 2000, 5(Suppl. 1), s. 151.
27. Vitale, C., Gebara, O., Mercuro, G. et al.: Value of C-reaktive protein levels and IL-6 in predicting events levels ion women at encreased cardiovascular risk. Maturitas, 2005, 50, s. 239-246.
28. Pradhan, A. D., Manson, J. E., Rossouw, J. E. et al.: Inflamnatory biomarkers, HRT, and incident coronary heart disease: prospective analysis form the WHI observational study. JAMA, 2002, 288, s. 980-987.
29. Kuneš, P.: CRP v patogenezi aterosklerózy: přednosti a úskalí "Mohučské hypotézy". Čas. Lék. čes., 2005, 144, s. 25.
30. Eilertsen, A. L., Hoibraaten, E., Os, I. et al.: The effect of oral and transdermal HRT on CRP levels and other inflammatory markers in women with high risk of trombosis. Maturitas, 2005, 52, s. 111-118.
31. Walsh, B. W., Paul, S., Wild, R. A. et al.: The effects of HRT and raloxifenc on C-reactive protein and homocysteine in healthy postmenopausal women. J. Clin. Endocrinol. Metab., 2000, 85, s. 214-218.
32. Koh, K. K., Ahn, J. Y., Jin, D. K. et al.: Signifikant differential effects of HT or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-control, crossover study. Arterioscler. Tromb. Vasc. Biol., 2003, 23, s. 1889-1889.